DNA vaccines: ready for prime time?

Nat Rev Genet. 2008 Oct;9(10):776-88. doi: 10.1038/nrg2432.


Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animal Diseases / therapy
  • Animals
  • Clinical Trials as Topic / trends*
  • Clinical Trials as Topic / veterinary
  • Drug Evaluation, Preclinical / trends
  • Humans
  • Immunity / physiology
  • Immunotherapy / trends
  • Immunotherapy / veterinary
  • Models, Biological
  • Vaccines, DNA / adverse effects
  • Vaccines, DNA / therapeutic use*


  • Vaccines, DNA